Rina Mehta

654 total citations
17 papers, 164 citations indexed

About

Rina Mehta is a scholar working on Pathology and Forensic Medicine, Economics and Econometrics and Rheumatology. According to data from OpenAlex, Rina Mehta has authored 17 papers receiving a total of 164 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 4 papers in Economics and Econometrics and 3 papers in Rheumatology. Recurrent topics in Rina Mehta's work include Multiple Sclerosis Research Studies (8 papers), Acute Lymphoblastic Leukemia research (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Rina Mehta is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Acute Lymphoblastic Leukemia research (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Rina Mehta collaborates with scholars based in United States and India. Rina Mehta's co-authors include Corey Pelletier, Machaon Bonafede, Léorah Freeman, Robert J. Shapiro, Jeffrey A. Snyder, Sachin A. Shah, James Signorovitch, Elyse Swallow, Oscar Patterson‐Lomba and James K. Sheffield and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and The American Journal of the Medical Sciences.

In The Last Decade

Rina Mehta

16 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rina Mehta United States 8 82 27 26 26 24 17 164
Genta Ishikawa Japan 8 36 0.4× 66 2.4× 37 1.4× 34 1.3× 30 1.3× 22 274
Lúcia Costa Portugal 10 26 0.3× 98 3.6× 20 0.8× 16 0.6× 30 1.3× 67 209
Yuka Kosuga Japan 6 59 0.7× 16 0.6× 23 0.9× 4 0.2× 32 1.3× 8 316
Owain Williams United Kingdom 5 223 2.7× 58 2.1× 14 0.5× 20 0.8× 28 1.2× 7 286
Tate Johnson United States 8 27 0.3× 111 4.1× 9 0.3× 28 1.1× 28 1.2× 20 193
E Musiej-Nowakowska Poland 6 28 0.3× 38 1.4× 16 0.6× 10 0.4× 28 1.2× 12 98
Clara Leroy France 7 23 0.3× 24 0.9× 38 1.5× 7 0.3× 44 1.8× 14 247
Guillermo Alcaín Spain 6 21 0.3× 19 0.7× 17 0.7× 11 0.4× 56 2.3× 14 165
Marina Šprem Goldštajn Croatia 9 15 0.2× 33 1.2× 23 0.9× 13 0.5× 19 0.8× 26 257
Jiacai Cho Singapore 7 28 0.3× 99 3.7× 13 0.5× 5 0.2× 49 2.0× 19 146

Countries citing papers authored by Rina Mehta

Since Specialization
Citations

This map shows the geographic impact of Rina Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rina Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rina Mehta more than expected).

Fields of papers citing papers by Rina Mehta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rina Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rina Mehta. The network helps show where Rina Mehta may publish in the future.

Co-authorship network of co-authors of Rina Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Rina Mehta. A scholar is included among the top collaborators of Rina Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rina Mehta. Rina Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mehta, Rina, et al.. (2024). Consider conversion disorder in patients with a prolonged case of serotonin syndrome. The American Journal of the Medical Sciences. 367. S259–S259.
2.
Cristino, Joaquim, et al.. (2023). Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study. SHILAP Revista de lepidopterología. 14. 100476–100476. 7 indexed citations
3.
Fox, Robert J., et al.. (2022). Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis. BMC Neurology. 22(1). 211–211. 14 indexed citations
4.
5.
6.
Freeman, Léorah, et al.. (2021). Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients. ClinicoEconomics and Outcomes Research. Volume 13. 65–75. 12 indexed citations
7.
Singer, B., et al.. (2021). A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping. Patient Preference and Adherence. Volume 15. 975–987. 5 indexed citations
8.
Bonafede, Machaon, et al.. (2020). PND19 PRODUCTIVITY LOSS AMONG CAREGIVERS OF PATIENTS WITH MS. Value in Health. 23. S261–S262. 1 indexed citations
9.
Bowen, James D., Rina Mehta, Corey Pelletier, et al.. (2020). Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Advances in Therapy. 37(7). 3163–3177. 12 indexed citations
10.
Kantor, Daniel, Rina Mehta, Corey Pelletier, et al.. (2020). Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis. Clinical Therapeutics. 42(11). 2136–2147.e3. 3 indexed citations
11.
Swallow, Elyse, Oscar Patterson‐Lomba, Rajeev Ayyagari, et al.. (2020). Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. Journal of Comparative Effectiveness Research. 9(10). 737–750. 2 indexed citations
12.
Bonafede, Machaon, et al.. (2020). Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open. 5(1). 23–34. 5 indexed citations
13.
Swallow, Elyse, Oscar Patterson‐Lomba, Lei Yin, et al.. (2020). Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. Journal of Comparative Effectiveness Research. 9(4). 275–285. 35 indexed citations
14.
Feldman, Steven R., Corey Pelletier, Kathleen Wilson, et al.. (2019). Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. Journal of Comparative Effectiveness Research. 8(9). 699–709. 7 indexed citations
15.
Feldman, Steven R., Corey Pelletier, Kathleen Wilson, et al.. (2018). Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. Journal of Comparative Effectiveness Research. 8(1). 45–54. 15 indexed citations
16.
Gupta, Siddhartha Datta, et al.. (2013). Nonfamilial cherubism. Journal of Indian Society of Pedodontics and Preventive Dentistry. 31(1). 43–47. 3 indexed citations
17.
Shah, Sachin A., Robert J. Shapiro, Rina Mehta, & Jeffrey A. Snyder. (2010). Impact of Enhanced External Counterpulsation on Canadian Cardiovascular Society Angina Class in Patients with Chronic Stable Angina: A Meta‐analysis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(7). 639–645. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Genta Ishikawa Breakdown of academic impact, for papers by Lúcia Costa Breakdown of academic impact, for papers by Yuka Kosuga Breakdown of academic impact, for papers by Owain Williams Breakdown of academic impact, for papers by Tate Johnson Breakdown of academic impact, for papers by E Musiej-Nowakowska Breakdown of academic impact, for papers by Clara Leroy Breakdown of academic impact, for papers by Guillermo Alcaín Breakdown of academic impact, for papers by Marina Šprem Goldštajn Breakdown of academic impact, for papers by Jiacai Cho
Rankless by CCL
2026